Corcept Therapeutics Incorporated (CORT) Q3 Revenue Reached $340.5M

What happened

Corcept Therapeutics reported Q3 2026 revenue of $340.5M and net income of $126.8M, compared with $256.1M and $43.0M, respectively, in Q2. It reiterated full-year 2026 revenue guidance of $1.1B–$1.2B and reported Lifyorli revenue of $91.4M.

Confirmed

Global impact / market context

Higher quarterly revenue and net income show stronger sequential results, while unchanged annual guidance means Corcept has not raised its full-year target. Lifyorli adds revenue to the oncology business, but without a stated comparison period, its reported increase cannot be assessed against a clear baseline.

Analyst inference

The update combines reported growth with a maintained outlook, rather than a forecast increase. Corcept also repurchased $43.7M of its common stock, using cash, while cash and investments rose to $662.3M from $544.6M in Q2; that balance may support future spending or trials.

Analyst inference

What to watch

1. Compare upcoming quarterly revenue with the reiterated $1.1B–$1.2B 2026 guidance; results below or above the pace needed could affect confidence in the annual outlook. Analyst inference
2. Watch whether Lifyorli revenue continues to grow and whether Corcept clarifies the comparison period behind its reported increase, helping assess the product’s contribution. Analyst inference
3. The company plans a Phase 3 ALS study next year, but has not provided a start date or trial design; those details would clarify timing and planned trial scope. Confirmed

Evidence

• Original source link unavailable